Methotrexate (hydrate)

Methotrexate (MTX) is similar in structure to folic acid (Cay-20515) and aminopterin (Cay-21802). It acts by inhibiting the metabolism of folic acid and blocking key enzymes in the synthesis of purines and pyrimidines required for cell proliferation. MTX is known to induce adenosine release, which mediates many of its anti-inflammatory effects, including the reduction of proinflammatory cytokines. Formulations containing MTX have been used as immunosuppressants, in the treatment of cancer, autoimmune disease, ectopic pregnancy, and for the induction of medical abortions. MTX formulations have been considered the gold standard of disease-modifying antirheumatic drug (DMARD) therapy to treat both the immune-inflammatory and joint destructive processes of rheumatoid arthritis.Formal Name: N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, hydrate. CAS Number: 133073-73-1. Synonyms: Amethopterin, CL 14,377, EMT 25299, MTX, NSC 740, R 9985. Molecular Formula: C20H22N8O5 . XH2O. Formula Weight: 454.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 14 mg/ml, DMSO: 3 mg/ml, PBS (pH 7.2): 1 mg/ml. lambdamax: 262, 299, 377 nm. SMILES: NC1=NC(N)=C2C(N=CC(CN(C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)C)=N2)=N1.O. InChi Code: InChI=1S/C20H22N8O5.H2O/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30,/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27),1H2/t13-,/m0./s1. InChi Key: FPJYMUQSRFJSEW-ZOWNYOTGSA-N.